XW013L9Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

New Technology›Anatomical Regions›Introduction

Billable / Specific Code

ICD-10-PCS XW013L9

CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.

XW013L9 is a billable ICD-10-PCS procedure code for Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code

XW013L9

Billable Status

Yes — Valid for Submission

Code Describes

Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

Parent Code

XW0

Short Description

Introduce Elranatamab in Subcu, Perc, New Tech 9

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

Position	Designation	Value	Meaning
1	Section	X	New Technology
2	Body System	W	Anatomical Regions
3	Operation	0	Introduction
4	BodyPart	1	Subcutaneous Tissue
5	Approach	3	Percutaneous
6	Device/Substance/Technology	L	Elranatamab Antineoplastic
7	Qualifier	9	New Technology Group 9

Code History

Replaces previously assigned code(s):

3E01305 — Introduction of Oth Antineoplastic into Subcu, Perc Approach

Similar Procedure Codes

Filter related codes list:

Questions About XW013L9

Is XW013L9 a billable code?

Yes. XW013L9 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW013L9 mean?

XW013L9 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 1 is the BodyPart (Subcutaneous Tissue); the 5th character 3 is the Approach (Percutaneous); the 6th character L is the Device/Substance/Technology (Elranatamab Antineoplastic); the 7th character 9 is the Qualifier (New Technology Group 9).